TB-500

TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid peptide conserved across species and expressed in various tissues. Research has shown that TB-500 interacts with actin, a protein crucial for cell migration and tissue remodeling. This interaction promotes actin polymerization, which is essential for angiogenesis and cell migration to injury sites.

Research has demonstrated that TB-500 modulates the expression of genes involved in inflammation, wound healing, and tissue regeneration. For instance, it has been found to upregulate matrix metalloproteinases (MMPs), enzymes key to extracellular matrix remodeling and wound healing.

• Wound healing: TB-500 has been shown to enhance keratinocyte and fibroblast migration, stimulate angiogenesis, and reduce inflammation, contributing to faster healing in various wound types.
• Anti-inflammatory effects: Studies have demonstrated TB-500's ability to reduce pro-inflammatory cytokine production and increase anti-inflammatory cytokine levels in various inflammatory conditions.
• Hair growth stimulation: Research using mammalian models has found that TB-500 can increase hair follicle size and promote the transition from telogen to anagen phase.
• Neuroprotection: Studies have explored TB-500's potential to reduce neuroinflammation, oxidative stress, and apoptosis in models of neurological disorders.
• Cardioprotection: In mammalian models of myocardial infarction, TB-500 has been shown to reduce infarct size, improve cardiac function, and promote angiogenesis.

Based on the available preclinical data, the most common side effects associated with TB-500 treatment include:

• Injection site reactions (pain, redness, swelling)
• Headache
• Nausea
• Dizziness
• Fatigue

Note: The safety profile of TB-500 has not been fully established, and further clinical studies are needed to fully evaluate the potential for side effects and long-term safety of TB-500 in mammals.

TB-500, a synthetic version of the naturally occurring peptide Thymosin Beta-4, has shown remarkable potential in various research settings. The peptide has been extensively studied for its ability to promote wound healing, reduce inflammation, stimulate hair growth, provide neuroprotection, and offer cardioprotection. TB-500 exerts its effects through multiple mechanisms, including its interaction with actin, modulation of gene expression, and regulation of inflammatory pathways.

As a research tool, TB-500 offers a valuable opportunity to explore the complex mechanisms underlying wound healing, inflammation, and tissue regeneration. The insights gained from these studies may pave the way for the development of novel therapeutic strategies for a wide range of conditions, from skin wounds and hair loss disorders to neurodegenerative diseases and cardiovascular disorders.

1. Bock-Marquette I, Maar K, Maar S, Lippai B, Faskerti G, Gallyas F Jr, Olson EN, Srivastava D. Thymosin beta-4's new directions towards developing prosperous anti-aging regenerative therapies. Int Immunopharmacol. 2023;116:109741. doi: 10.1016/j.intimp.2023.109741. Epub 2023 Jan 27. PMID: 36709593.
2. Belsky JB, Rivers EP, Filbin MR, Lee PJ, Morris DC. Thymosin beta 4 regulation of actin in sepsis. Expert Opin Biol Ther. 2018 Jul;18(sup1):193-197. doi: 10.1080/14712598.2018.1448381. Epub 2018 Mar 6. PMID: 29508629; PMCID: PMC6556887.
3. Bubb MR. Thymosin beta 4 interactions. Vitam Horm. 2003;66:297-316. doi: 10.1016/s0083-6729(03)01008-2. PMID: 12852258.
4. Sosne G. Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opin Biol Ther. 2018 Jul;18(sup1):99-104. doi: 10.1080/14712598.2018.1486818. PMID: 30063853.
5. Pipes GT, Yang J. Cardioprotection by Thymosin Beta 4. Vitam Horm. 2016;102:209-26. doi: 10.1016/bs.vh.2016.01.004. Epub 2016 May 31. PMID: 27450736.
6. Song K, Han HJ, Kim S, Kwon J. Thymosin beta 4 attenuates PrP(106-126)-induced human brain endothelial cell dysfunction. Eur J Pharmacol. 2020 Feb 15;869:172891. doi: 10.1016/j.ejphar.2019.172891. Epub 2019 Dec 23. PMID: 31812611.
7. Choi J, Cho Y, Choi H, Lee S, Han H, Lee J, Kwon J. Thymosin Beta 4 Inhibits LPS and ATP-Induced Hepatic Stellate Cells via the Regulation of Multiple Signaling Pathways. Int J Mol Sci. 2023 Feb 8;24(4):3439. doi: 10.3390/ijms24043439. PMID: 36834849; PMCID: PMC9959661.
8. Kim J, Jung Y. Thymosin Beta 4 Is a Potential Regulator of Hepatic Stellate Cells. Vitam Horm. 2016;102:121-143. doi: 10.1016/bs.vh.2016.04.011. Epub 2016 May 31. PMID: 27450733.
9. Han HJ, Kim S, Kwon J. Thymosin beta 4-Induced Autophagy Increases Cholinergic Signaling in PrP(106-126)-treated HT22 Cells. Neurotox Res. 2019 Jul;36(1):58-65. doi: 10.1007/s12640-018-9985-0. Epub 2018 Dec 15. PMID: 30554390.
10. Kim J, Jung Y. Potential role of thymosin Beta 4 in liver fibrosis. Int J Mol Sci. 2015 May 8;16(5):10624-35. doi: 10.3390/ijms160510624. PMID: 26006229; PMCID: PMC4463665.

COA image will be added when available.

All products on this site are for research and development use only. Products are not for human consumption of any kind. The statements made on this website have not been evaluated by the US Food and Drug Administration. Neither the products described nor the company are intended to diagnose, treat, cure, or prevent any disease.